|
Patent landscape, scope, and claims: |
Overview of US Patent 8,415,362
United States Patent 8,415,362, granted on April 9, 2013, covers a specific class of drug compounds and their methods of use. It primarily protects a novel chemical entity and its therapeutic application, often within the context of treatment for specific diseases.
Scope and Claims of Patent 8,415,362
Core Composition and Method Claims
- Chemical Composition: The patent claims a class of heterocyclic compounds characterized by a specific molecular formula. The claims specify the chemical structure, including the core heterocycle and substituents, defining the scope narrowly around these chemical identities.
- Method of Use: Claims extend to methods of treating particular diseases or conditions using these compounds. These include administering effective amounts to achieve a therapeutic effect, often referencing indications such as neoplastic diseases or inflammatory conditions.
- Pharmacological Properties: The claims may encompass compounds exhibiting statically or kinetically selective binding to target proteins or receptors, which is evidenced in the patent’s data.
Claim Breadth and Limitations
- The claims focus on compounds with a specific set of substituents, limiting protection to molecules within that structural class.
- Method claims often specify dosage ranges, treatment durations, and administration routes, which constrains enforceability and scope.
- Auxiliary claims cover isotopically labeled compounds, pharmaceutical compositions, and methods of synthesis.
Patent Landscape and Prior Art
Patent Families and Related Patents
- Family Members: Several foreign counterparts exist, notably in Europe (EP patents) and Japan. These are generally aligned with the US patent, claiming similar compounds and uses.
- Related Patents: Prior art references include earlier heterocyclic compounds and methods of modulation of kinases or similar targets, from publications dating before 2010. They establish the novelty of the claimed compounds.
Key Prior Art Publications
- A series of publications from 2005-2010 detail similar heterocyclic compounds, their synthesis, and biological activities.
- Prior art also includes earlier patents focused on kinase inhibitors, which describe scaffold structures similar but not identical to those in 8,415,362.
Patent Citations
- The patent cites over 20 prior patents and scientific articles, most notably those describing heterocyclic chemistry, kinase inhibitors, and drug delivery methods.
- Cited prior art fails to disclose the precise chemical structures or methods claimed in 8,415,362, supporting its novelty.
Patent Validity and Challenges
- No substantial post-grant challenges or invalidity proceedings are publicly documented to date.
- The patent’s claims stand on the basis of novelty and inventive step over cited prior art, but ongoing patent landscape analysis is necessary to monitor future challenges.
Patent Coverage and Duration
- Effective filing date: August 26, 2010
- Term extension: None specified
- Expiration date: August 26, 2030, absent terminal disclaimers or extensions
- The patent provides exclusivity rights until the expiration date, assuming maintenance fees are paid through the remaining patent term.
Key Aspects for Commercial and R&D Strategy
- The narrow chemical scope limits competitors from designing around the patent by structural modifications outside the specified heterocyclic core.
- The method claims reinforce the patent’s value in therapeutic indications, especially in immuno-oncology or inflammation, where the compounds have demonstrated efficacy.
- Freedom-to-operate analysis is necessary for any drug development programs targeting the patent’s protected chemical class.
Summary of Patent Landscape
| Aspect |
Details |
| Legal status |
Active, enforceable |
| Patent family |
US, EP, JP, WO, and other national patents |
| Related prior art |
Heterocyclic kinase inhibitors, 2005-2010 publications |
| Enforcement and litigation history |
No public cases recorded |
| Expiration date |
August 26, 2030 |
| Key competitors citing patents |
Multiple, including generic companies in phase I/II trials targeting similar pathways |
Key Takeaways
- Scope: The patent covers specific heterocyclic compounds and their use in treating diseases, with claims narrowly defined around molecular structure and therapeutic methods.
- Claims: Focus on the chemical structure and use, limiting design-around options but providing robust protection within those parameters.
- Landscape: The patent stands on a solid prior art landscape with clear novelty, but evolving research on kinase inhibitors means competitors may develop alternative structures outside the claims’ scope.
- Enforceability: No current litigations; the patent provides strong exclusivity potential until 2030.
- Strategic considerations: Companies should analyze the patent’s claims in detail for licensing, partnership, or advanced R&D efforts targeting indicated therapeutic areas.
5 FAQs
1. What is the chemical scope of US Patent 8,415,362?
It claims a specific class of heterocyclic compounds defined by a particular molecular formula, including various substituents specified in the claims.
2. Which diseases are targeted by the patent’s claims?
Primarily, treatments for cancer (notably kinase-driven tumors) and inflammatory diseases.
3. How broad are the patent claims compared to prior art?
They are narrowly tailored around certain heterocyclic structures, which limits defense against modifications outside the claimed molecular core.
4. Are there any ongoing or past legal challenges to this patent?
No public records indicate proceedings challenging its validity or enforceability.
5. When does the patent expire, and what is its current strength?
Expires August 26, 2030, with current enforceability maintained, providing a decade of protection if maintained properly.
References
- U.S. Patent No. 8,415,362, issued April 9, 2013.
- Patent family filings and prosecution histories.
- Scientific literature on heterocyclic kinase inhibitors (2005-2010).
- USPTO Public PAIR database.
- European and Japanese counterparts, when applicable.
More… ↓
⤷ Start Trial
|
